Postdoctoral Associate, RNAi Platform
![]() | |
![]() United States, Massachusetts, Cambridge | |
![]() 675 West Kendall Street (Show on map) | |
![]() | |
Overview
Alnylam Research post-doc program is designed to advance RNAi research with fresh perspectives and ideas from recent PhDs and thrive in vibrant research environment at Alnylam. Postdoc fellows will be provided the opportunity to collaborate with colleagues working in diverse disciplines including bioinformatics, RNAi lead discovery, oncology, RNAi biology, target discovery, and clinical development. They will be provided necessary budgetary support and infrastructure to execute the projects. In addition, postdocs are encouraged to participate at scientific conferences, collaborate with external partners as appropriate and publish high impact papers. The Research department at Alnylam is seeking a passionate post-doctoral fellow to join our LC/MS-based engineering group dedicated to preclinical target validation, biomarker discovery, and biophysical modeling to support novel delivery solutions for our RNAi therapeutics. The successful candidate will have a strong theoretical foundation in mass spectrometry to develop state-of-the-art workflows in spatial and single-cell proteomics. He/She will also have a background in computational modeling to apply AI/ML algorithms for protein structure and function prediction spanning preclinical model species and human. It is expected that the research conducted by the postdoctoral fellow will result in multiple high impact publications after filing appropriate patents and contribute to the Alnylam pipeline. Key Responsibilities
Qualifications
Alnylam's Postdoctoral Program
About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. > |